Urticaria highlights from AAD 2025 include late-breaking results from a phase 1b/2a study of the anti-c-Kit antibody ...
Adults with chronic spontaneous urticaria experienced greater mortality, probably due to increased risks for comorbidities, ...
Dr Adam Friedman discusses the clinical impact of CSU updates, highlighting emerging therapies, dietary insights, and patient ...
The following is a summary of “Patient and physician perspectives on disease burden in chronic spontaneous urticaria,” ...
Cycle Pharmaceuticals Limited (Cycle) is pleased to announce that Cycle Vita is now available with BAFIERTAM, expanding its patient support services in MS, following the acquisition of Banner Life ...
Ascilion's products for dermal interstitial fluid sampling will be the focus of six different presentations at the Microneedles 2025 Conference.</ ...
Dupixent (dupilumab) is available in Japan in a 300 mg dose as a pre-filled syringe or pre-filled pen and is now available ...
Edex Live on MSN6d
The chart med students didn’t know they needed: This haematologist’s post is going viralMedical Twitter has found its new favourite resource — and it’s making life a lot easier for medical students. Abdul Muqtadir ...
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Strategic ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback